Patara Pharma (United States)

Comparative study of the efficacy and safety of Ranquilon and Afobazol in the treatment of patients with anxiety associated with neurasthenia and adjustment disorders. (Results of an open, randomized, multicenter, phase IV clinical study)

Objective. To evaluate the efficacy and safety of Ranquilon1 at 6 mg daily, compared with Afobazol (fabomotizole) at 30 mg daily, for the treatment of patients with anxiety associated with neurasthenia and adjustment disorders. Material and methods. The clinical study included 20...